Adamas Pharmaceuticals, based in Emeryville, CA announced that the FDA has granted Orphan Drug Designation (ODD) for ADS-5120 for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD). ADS-5120 is a high dose, extended-release formula of amantadine HCl that is administered once daily at bedtime. LID is a complication that induced by long-term treatment with levodopa, the most widely used medicine to treatment of PD. Currently, there is no approved drug available to treat LID. Previous Phase II/III studies with ADS-5120 have shown positive results and Adamas is sponsoring multiple phase III clinical trials evaluating its efficacy in PD patients with LID.